Select Publications
Conference Abstracts
, 2018, 'Integrated genomics: drug screening and personalized xenograft development approach to identify precision treatments for aggressive pediatric brain tumors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-137
, 2018, 'Targeting the polyamine pathway as a novel therapeutic treatment against diffuse intrinsic pontine glioma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-4800
, 2018, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-138
, 2018, 'EAPH-09. POTENT CLINICAL AND RADIOLOGICAL RESPONSE TO LAROTRECTINIB IN FIRST CASE OF TRK FUSION HIGH GRADE GLIOMA', in Neuro-oncology, Vol. 20, pp. i67 - i67
, 2018, 'PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia', in ESMO Open, Elsevier BV, Vol. 3, pp. A238 - A238, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.563
, 2018, 'Zero childhood cancer – Accelerating translation of experimental oncology: Better matching drug to target', in Pathology, Elsevier BV, Vol. 50, pp. S31 - S31, http://dx.doi.org/10.1016/j.pathol.2017.12.072
, 2017, 'REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, SPAIN, Madrid, Vol. 102, pp. 27 - 27, presented at 22nd Congress of the European-Hematology-Association, SPAIN, Madrid, 22 June 2017 - 25 June 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404127001055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2017, 'Pilot study of a comprehensive precision medicine platform for children with high-risk cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 06 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.10539
, 2016, 'HG-20COMBINATION OF EPIGENETIC MODIFIERS CBL0137 AND PANOBINOSTAT IS HIGHLY POTENT IN VITRO AND IN VIVO FOR DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-oncology, Vol. 18, pp. iii51 - iii51
, 2015, 'Selective and rapid killing of mixed lineage leukemia and CALM-AF10 leukemia by SM7, a novel small molecule identified by chemical library screening', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, FL, Fort Lauderdale, Vol. 76, presented at AACR Special Conference on Advances in Pediatric Cancer Research - From Mechanisms and Models to Treatment and Survivorship, FL, Fort Lauderdale, 09 November 2015 - 12 November 2015, http://dx.doi.org/10.1158/1538-7445.PEDCA15-B23
, 2015, 'The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1611
, 2015, 'The long noncoding RNA MALAT1 promotes hypoxia-driven angiogenesis by upregulating pro-angiogenic gene expression in neuroblastoma cells', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-146
, 2011, 'THE VALUE OF MONITORING FOR MRD AT LATE TIMEPOINTS IN PAEDIATRIC ALL TREATMENT', in PEDIATRIC BLOOD & CANCER, WILEY PERIODICALS, INC, Vol. 57, pp. 707 - 707, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295239600003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2011, 'Development of organ-selective neuroblastoma cell lines to identify genes mediating bone marrow and liver colonization', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-5237
, 2011, 'SIRT1 promotes N-Myc oncogenesis stabilizing N-Myc protein', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-3027
, 2008, 'The value of monitoring for minimal residual disease post-transplant in children with acute lymphoblastic leukaemia', in British Journal of Haematology, Blackwell Publishing Ltd, Oxford, England, pp. 102 - 102, presented at Abstracts of the British Society of Haematology 48th Annual Scientific Meeting, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium
, 2006, 'Relapse in children with acute lymphoblastic leukaemia is associated with selection of a pre-existing drug resistance subclone', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Vol. 4, pp. 81 - 81, http://dx.doi.org/10.1016/S1359-6349(06)70257-9
, 2006, 'Sensitisation of neuroblastorna tumours to chemotherapy by use of a novel class of MRP1 small molecule inhibitor', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Vol. 4, pp. 54 - 54, http://dx.doi.org/10.1016/S1359-6349(06)70175-6
, 1985, 'MONITORING REPAIR AND REPLICATIVE-INDUCED STRUCTURAL-CHANGE IN CULTURES OF PROLIFERATING MAMMALIAN-CELLS', in MEDICAL AND PEDIATRIC ONCOLOGY, WILEY-LISS, Vol. 13, pp. 135 - 135, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1985AHS3500014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Preprints
, 2025, Single-cell RNA-sequencing of cerebral spinal fluid identifies circulating tumour cells in children with brain cancer, http://dx.doi.org/10.64898/2025.12.18.694991
, 2025, The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity., http://dx.doi.org/10.21203/rs.3.rs-7014295/v1
, 2025, Expanding the utility of transcriptome analysis for mutation detection in high-risk childhood precision oncology, http://dx.doi.org/10.1101/2025.06.25.661445
, 2025, Inclusion of JNK-independent drugs within multi-agent chemotherapy improves response in relapsed high-risk neuroblastoma, http://dx.doi.org/10.1101/2025.04.26.650760
, 2024, The polyamine transporter ATP13A3 mediates DFMO-induced polyamine uptake in neuroblastoma, http://dx.doi.org/10.1101/2024.02.20.581161
, 2024, Integrated germline and somatic molecular profiling to detect cancer predisposition has a high clinical impact in poor-prognosis paediatric cancer, http://dx.doi.org/10.1101/2024.08.08.24311493
, 2023, Precision-guided treatment improves outcomes for children with high-risk cancers, http://dx.doi.org/10.21203/rs.3.rs-3376668/v1
, 2022, A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer, http://dx.doi.org/10.1101/2022.09.16.508179
, 2022, Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusions, http://dx.doi.org/10.21203/rs.3.rs-1714034/v1
, 2022, Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusions, http://dx.doi.org/10.1101/2022.06.22.497105
, 2022, The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation, http://dx.doi.org/10.1101/2022.10.10.511510
, 2019, Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design, http://dx.doi.org/10.1101/566455
Other
, 2025, Data from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.c.7948327
, 2025, Figure 2 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644702
, 2025, Figure 3 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644699
, 2025, Figure 4 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644696
, 2025, Figure 5 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644693
, 2025, Figure S1 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644690
, 2025, Figure S2 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644687
, 2025, Figure S3 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644684
, 2025, Figure S4 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644681
, 2025, Table 1 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644678
, 2025, Table 2 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644675
, 2025, Table S1 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644672
, 2025, Table S2 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644669
, 2025, Zero Childhood Cancer: a national approach to improving outcomes of Australian children with cancer through multiomic precision medicine, Elsevier BV, http://dx.doi.org/10.1016/j.pathol.2024.12.099
, 2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498
, 2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498.v3
, 2023, Supplementary Figures and Figure Legends from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000213.v1
, 2023, Supplementary Figures and Figure Legends from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000213
, 2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000210.v1